DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB...
Transcript of DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB...
![Page 1: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/1.jpg)
DEB for Femoropopliteal Lesions: Latest Trial Results
German Heart Center M nich GermanMunich, Germany
![Page 2: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/2.jpg)
P t ti l fli t f i t tPotential conflicts of interest
Speaker’s name:
I have the following potential conflicts of interest to report:
Research contracts Consulting Employment in industry Stockholder of a healthcare company O f h l h Owner of a healthcare company Other(s)
X I do not have any potential conflict of interest
![Page 3: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/3.jpg)
Eur Heart J 2011;32, 2851–2906
J Am Coll Cardiol 2013;61, 13
![Page 4: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/4.jpg)
Why DEB for femoropopliteal lesions?
Biomechanical forces challenging femoropopliteal artery territory
Scheinert D, J Am Coll Cardiol 2005;45:312–5Scheinert D, J Am Coll Cardiol 2005;45:312 5
![Page 5: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/5.jpg)
for femoropopliteal lesions
In femoropopliteal arterial disease, PCB therapy is associated with superior antirestenotic efficacy as compared with UCB angioplasty with no evidence of a differential safety profile g p y y p
Absolute risk reduction = 25.5% [17.0%, 34.1%]Number needed to treat = 4 [2.9–5.9]
Cassese S, Fusaro M, et al. Circ Cardiovasc Interv. 2012;5:582‐589
![Page 6: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/6.jpg)
DEB for femoropopliteal lesions:
105 patients72.4% primary patency at 2‐year FU
Micari A, Biamino G, et al. J Am Coll Cardiol Intv 2013;6:282–9
![Page 7: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/7.jpg)
DEB for femoropopliteal
l dCassese S, Fusaro M, et al. Circ Cardiovasc Interv. 2012;5:582‐589
Fusaro M, Cassese S, et al. EuroIntervention 2013;8:1342‐1345
![Page 8: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/8.jpg)
The adjunctive use of DEB for the treatment of SFA‐ISR represents a potentially safe and effective therapeutic strategy.
Stabile E, Rubino P, et al. J Am Coll Cardiol 2012;60:1739–42
![Page 9: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/9.jpg)
for femoropopliteal lesions
Pre‐dilatation with DEB prior to Nitinol Stent reduces restenosis and TLR at 12‐month vs. PTA + Stent
Liistro F, et al. TCT 2012
![Page 10: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/10.jpg)
for femoropopliteal lesionsThe performance of paclitaxel‐coated balloon (PCB) or primary bare nitinol stent (BNS) versus
uncoated balloon angioplasty (UCB) for femoropopliteal artery disease and the relative efficacy and safety of PCB versus BNS are still debatedsafety of PCB versus BNS are still debated.
Paclitaxel‐coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta‐p y p p yanalysis of randomized trials versus uncoated balloon and an adjusted indirect comparison
Fusaro M, Cassese S, et al. LINC 2013
![Page 11: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/11.jpg)
TLR
Median follow‐up was 24 months [IQR 12‐24] in the PCB subgroup and 12 months
[IQR 12‐24] in the BNS subgroup
Restenosis
At indirect comparison, paclitaxel‐coated balloon may have comparable antirestenotic efficacy and safety of bare nitinol stent,
Fusaro M, Cassese S, et al. LINC 2013
![Page 12: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/12.jpg)
for femoropopliteal lesions:
Vs Vs PTAPTA DEBDEB StentStent AthAth
PTAPTA ‐‐ ‐‐ ‐‐PTAPTA ‐‐ ‐‐ ‐‐
INPACT SFA I; Tepe G INPACT SFA I; Tepe G ‐‐NCT01175850NCT01175850
ADCAT; Zeller TADCAT; Zeller TADCAT; Zeller, T ADCAT; Zeller, T ‐‐NCT01763476NCT01763476
INPACT SFA II; Medtronic INPACT SFA II; Medtronic ‐‐NCT01566461NCT01566461
DEBDEB ‐‐ISARISAR‐‐STATH; Fusaro M STATH; Fusaro M ‐‐
NCT00986752NCT00986752
COPA CABANA; Tepe G COPA CABANA; Tepe G ‐‐NCT01594684NCT01594684
AdvanceAdvance® 18 PTX;® 18 PTX; ScheinertScheinert DD ‐‐AdvanceAdvance 18 PTX; 18 PTX; ScheinertScheinert DD ‐‐NCT00776906NCT00776906
DEFINITIVE AR; Zeller TDEFINITIVE AR; Zeller TLEVANT 2; LEVANT 2; ScheinertScheinert D D ‐‐
NCT01412541NCT01412541 DEFINITIVE AR; Zeller T DEFINITIVE AR; Zeller T ‐‐NCT01366482NCT01366482
NCT01412541NCT01412541
LEVANT Japan; LEVANT Japan; IidaIida O O ‐‐NCT01816412NCT01816412
StentStent ‐‐REAL PTX; Peeters P REAL PTX; Peeters P ‐‐
NCT01728441NCT01728441‐‐
AthAthAthAth ‐‐ ‐‐ ‐‐
![Page 13: DEB for Femoropopliteal Lesions: Latest Trial Resultssummitmd.com/pdf/pdf/PM0200_Fusaro.pdf · DEB for Femoropopliteal Lesions: Latest Trial Results GermanHeartCenter MnichMunich,](https://reader031.fdocument.pub/reader031/viewer/2022030406/5a8101367f8b9a0c748cd6e7/html5/thumbnails/13.jpg)
Conclusions
Yet in the “stent era”, the main limitation of endovascular treatment modalities in the femoropopliteal tract is the high rate of recurrent lesions necessitatingthe femoropopliteal tract is the high rate of recurrent lesions necessitating reinterventions
DEB may offer enhanced antirestenotic efficacy versus plain angioplasty, without safety concerns
DEB maybe used as a successful and reproducible strategy for patients presenting with in‐stent restenosis of femoropopliteal arteries, with definitive, large‐scale data still awaited
The supposed comparable efficacy of DEB versus bare nitinol as well as drug‐The supposed comparable efficacy of DEB versus bare nitinol as well as drugeluting stenting awaits properly‐designed, randomized controlled trials
Whether guidelines writing‐authorities should encourage replacing uncoated balloon angioplasty with DEB remains a matter of great debate